---
title: "Maze Therapeutics Announces $150 Million Oversubscribed Private Placement to Advance Kidney and Metabolic Disease Treatments"
description: "Maze Therapeutics, Inc. has announced a $150 million oversubscribed private placement to advance treatments for kidney and metabolic diseases. The agreement includes the sale of 4,000,002 shares at $1"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/256913548.md"
published_at: "2025-09-11T11:35:50.000Z"
---

# Maze Therapeutics Announces $150 Million Oversubscribed Private Placement to Advance Kidney and Metabolic Disease Treatments

> Maze Therapeutics, Inc. has announced a $150 million oversubscribed private placement to advance treatments for kidney and metabolic diseases. The agreement includes the sale of 4,000,002 shares at $16.25 each and 5,231,090 pre-funded warrants at $16.249 each. The funds will support the development of MZE829 and MZE782, among other initiatives. The placement is expected to close on September 12, 2025, subject to customary conditions.

Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company focused on small molecule precision medicines for kidney and metabolic diseases, has announced a securities purchase agreement for an oversubscribed private placement, raising approximately $150.0 million. The deal involves the sale of 4,000,002 shares of common stock at $16.25 per share, alongside 5,231,090 pre-funded warrants at $16.249 per warrant. J.P. Morgan, Leerink Partners, TD Cowen, and Guggenheim Securities are acting as joint placement agents. Proceeds will support the development of MZE829 for APOL1-mediated kidney disease, Phase 2 trials of MZE782 for phenylketonuria and chronic kidney disease, research initiatives, the Compass platform, and general corporate purposes. The private placement is anticipated to close on September 12, 2025, pending customary conditions. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Maze Therapeutics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: GNW9527269-en) on September 11, 2025, and is solely responsible for the information contained therein. © Copyright 2025 - Public Technologies (PUBT)

### Related Stocks

- [MAZE.US - Maze Therapeutics](https://longbridge.com/en/quote/MAZE.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Maze Therapeutics 強調即將發佈的 MZE829 腎臟數據，並在峯會上制定 MZE782 的第二階段計劃 | Maze Therapeutics（納斯達克股票代碼：MAZE）正在推進一種以基因為驅動的藥物開發方法，專注於腎臟和代謝疾病。首席執行官 Jason Coloma 強調了兩個關鍵項目：MZE829 用於 APOL1 介導的腎臟疾病，臨牀數據 | [Link](https://longbridge.com/en/news/275972996.md) |
| Maze Therapeutics 展示了其在腎臟和代謝疾病治療方面的管線進展 | Maze Therapeutics Inc. 更新了其專注於腎臟和代謝疾病的產品線，重點介紹了其主導項目 MZE829，這是一種針對 APOL1 介導的腎臟疾病的 APOL1 抑制劑，目前正在進行第二階段臨牀試驗，預計將在 2026 年第一 | [Link](https://longbridge.com/en/news/272296525.md) |
| RBC 表示，福泰製藥在第三階段腎臟藥物數據公佈前正處於一個關鍵的轉折點 | RBC 表示，Vertex Pharmaceuticals 在即將發佈第三階段腎臟藥物數據之際正處於轉折點 | [Link](https://longbridge.com/en/news/275490601.md) |
| 威斯康星大學麥迪遜分校要求學生報告麻疹疫苗接種情況 | 威斯康星大學麥迪遜分校已要求學生披露其麻疹、腮腺炎和風疹等疾病的疫苗接種狀態，此舉是在校園內出現近期麻疹病例後實施的。該政策旨在增強公共健康意識，併為高風險學生提供更好的支持。此公告是在全國麻疹病例增加的背景下發布的，衞生官員呼籲進行疫苗接 | [Link](https://longbridge.com/en/news/275930065.md) |
| BioRestorative Therapies 公司定價 500 萬美元的股票發行 | BioRestorative Therapies (BRTX) 定價了一項公開發行，約為 1430 萬股及購買股票的認股權證，價格為每股 0.35 美元。淨收益將用於資助 BRTX-100 針對椎間盤/脊柱疾病的臨牀試驗、ThermoSte | [Link](https://longbridge.com/en/news/275707665.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.